Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye provides a short comment on Fluoguide’s Q4 earnings and the company's outlook for 2026.</li><li>The report contained no major surprises, which is typical for a pre-revenue biotech company.</li><li>Importantly, Fluoguide leaves behind a prosperous 2025, marked by a successful share issue, continued clinical progress and key regulatory advancements that have laid a strong foundation for the company’s next phase of development.</li></ul>

Redeye provides a short comment on Fluoguide’s Q4 earnings and the company's outlook for 2026.The report contained no major surprises, which is typical for a pre-revenue biotech company.Importantly, Fluoguide leaves behind a prosperous 2025, marked by a successful share issue, continued clinical progress and key regulatory advancements that have laid a strong foundation for the company’s next phase of development.

Fluoguide (Q4 Initial take): Key milestones to drive value in 2026